This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Shire Pharmaceuticals Group PLC
Drug Names(s): HGT-ROP-001, IGF-1/IGFBP3, iPlex, Premiplex, rhIGF-I/rhIGFBP-3, SomatoKine, Mecasermin rinfibate [rDNA origin] injection
Description: Somatokine is a combination of IGF-I, a protein integral to the actions of both insulin and growth hormone, with a secondary protein called binding protein-3 (BP-3), to which IGF-I binds and circulates throughout the human body in tandem. The binding protein extends the half life of IGF-I, such that Iplex is injected once-daily.
Insmed and Avecia
In July 2002, Insmed and Avecia announced anagreement for the manufacture of iPlex and its component proteins, IGF-1 and IGFBP-3.
Tercica and Genentech
In March 2007, Tercica, Insmed and Genentech entered a Settlement, License and Development Agreement that resolves all outstanding litigation between the companies, including the patent infringement suits brought by Tercica and Genentech against Insmed in the United States and United Kingdom, and the unfair business practices suit.
Insmed will no longer be able to provide iPlex in the U.S. for severe Primary IGF-1 Deficiency and the following indications: Primary IGF-1 Deficiency, Noonans Syndrome, Laron Syndrome, Growth Hormone Deficiency, and all other short stature indications; and Adult Growth Hormone Deficiency. These indications are collectively referred to as the TRCA/Genentech Indications.
The parties will form a joint development (and subsequently, a joint...See full deal structure in Biomedtracker
Partners: Roche Holding AG Ipsen SA Insmed, Inc.
Additional information available to subscribers only: